These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
414 related items for PubMed ID: 24814134
1. Target hematologic values in the management of essential thrombocythemia and polycythemia vera. Hernández-Boluda JC, Gómez M. Eur J Haematol; 2015 Jan; 94(1):4-11. PubMed ID: 24814134 [Abstract] [Full Text] [Related]
6. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. Lim Y, Lee JO, Kim SH, Kim JW, Kim YJ, Lee KW, Lee JS, Bang SM. Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883 [Abstract] [Full Text] [Related]
10. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Tefferi A. Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894 [Abstract] [Full Text] [Related]
12. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Landolfi R, Cipriani MC, Novarese L. Best Pract Res Clin Haematol; 2006 Jun; 19(3):617-33. PubMed ID: 16781491 [Abstract] [Full Text] [Related]
13. Contemporary approach to essential thrombocythemia and polycythemia vera. Aruch D, Mascarenhas J. Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193 [Abstract] [Full Text] [Related]
15. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Barbui T, Finazzi G. Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889 [Abstract] [Full Text] [Related]
16. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations]. Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L. Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861 [Abstract] [Full Text] [Related]
17. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Leone G, Barbui T, GIMEMA Chronic Myeloproliferative Neoplasms Working Party. Am J Hematol; 2010 Feb; 85(2):97-100. PubMed ID: 20052743 [Abstract] [Full Text] [Related]
18. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Gangat N, Wolanskyj AP, Schwager SM, Hanson CA, Tefferi A. Cancer; 2009 Dec 15; 115(24):5740-5. PubMed ID: 19806641 [Abstract] [Full Text] [Related]
19. [State-of-the-art management for essential thrombocythemia and polycythemia vera]. Sugimoto Y. Rinsho Ketsueki; 2021 Dec 15; 62(8):1050-1059. PubMed ID: 34497191 [Abstract] [Full Text] [Related]
20. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Falanga A, Marchetti M, Barbui T, Smith CW. Semin Hematol; 2005 Oct 15; 42(4):239-47. PubMed ID: 16210037 [Abstract] [Full Text] [Related] Page: [Next] [New Search]